Brief: Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update
03/06/2024 14:22
June 3 (Reuters) - Calidi Biotherapeutics Inc CLDI.A :
* CALIDI BIOTHERAPEUTICS PRESENTS CLD-101 PHASE 1 TRIAL
UPDATE AND
PRECLINICAL DATA HIGHLIGHTING RTNOVA AND CLD-201 AT 2024 ASCO
ANNUAL MEETING
* CALIDI BIOTHERAPEUTICS INC: SHOWCASED PRECLINICAL DATA ON
RTNOVA
(CLD-400) PLATFORM'S ABILITY TO SURVIVE BLOODSTREAM AND REACH
ALL TUMORS SYSTEMICALLY
Source text for Eikon: ID:nBw7F6mjNa
Further company coverage: CLDI.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma